Shire

Shire plc fact sheet

Profile

Shire is now the leading global biotechnology company focused on serving patients with rare diseases and other highly specialized conditions. These diseases are often misunderstood, undiagnosed and life-threatening. Our 22,000 employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.

Leading marketed products in our therapeutic areas**

Products	2015 sales (US$ million)
HEMATOLOGY ADVATE, ADYNOVATE, FEIBA, HEMOFIL M, OBIZUR, RECOMBINATE, RIXUBIS	3,627
IMMUNOLOGY* ARALAST, BUMINATE, CEPROTIN, FLEXBUMIN, GLASSIA, HYQVIA, GAMMAGARD / KIOVIG	2,516
HEREDITARY ANGIOEDEMA (HAE) & LYSOSOMAL STORAGE DISORDERS (LSD) CINRYZE, ELAPRASE, FIRAZYR, KALBITOR, REPLAGAL, VPRIV	2,399
NEUROSCIENCE ADDERALL XR, BUCCOLAM, INTUNIV, EQUASYM, VYVANSE	2,200
GASTROINTESTINAL (GI) & INTERNAL MEDICINE (IM) GATTEX/REVESTIVE, FOSRENOL, LIALDA / MEZAVANT, NATPARA, PENTASA, XAGRID	1,501
ONCOLOGY ONCASPAR	87

Number of employees by region



1 USA	59%
2 Europe	35%
3 Asia	5%
4 Latin America	1%

History

Shire was founded in 1986 in the UK. Since then, Shire has grown revenues from $648 million in 2000 to over $6 billion in 2015. The recent combination with Baxalta marks a significant step in our growth.

Exchange	Ticker	Date listed
London Stock Exchange	SHP	February 1996 (market cap. £107m)
Nasdaq	SHPG	April 1998

2011–2015 Growth

Revenue 2011-2015*
(US$ billion)



*From continuing operations

2015 Product sales by therapeutic area**

1 Hematology	29.4%
2 Immunology**	20.4%
3 HAE & LSD	19.5%
4 Neuroscience	17.8%
5 GI & IM	12.2%
6 Oncology	0.7%

2015 Product sales by region**

1 USA $7,769m	63%
2 International $4,561m	37%

**Includes Baxalta pro forma 2015 sales

Shire

R&D Pipeline

Stage	Phase 1	Phase 2	Phase 3	Registration	Recent Approvals
Number of programs	5	14	17	5	2

Global operations



Group headquarters
Main offices

Board of Directors

Susan Kilsby	Chairman and Non-Executive Director
Flemming Ornskov MD	Chief Executive Officer
Jeffrey Poulton	Chief Financial Officer
Dominic Blakemore	Non-Executive Director
Olivier Bohuon	Non-Executive Director
Bill Burns	Non-Executive Director
Gail D. Fosler	Non-Executive Director
Steven Gillis	Non-Executive Director
David Ginsburg	Non-Executive Director
Sara Mathew	Non-Executive Director
Anne Minto OBE	Non-Executive Director
Albert P.L. Stroucken	Non-Executive Director

Executive Committee

Flemming Ornskov MD	Chief Executive Officer
Ueli Fankhauser	Head, Global Product Strategy
Perry Sternberg	Head, US Commercial
Philip Vickers PhD	Head, Research and Development
Jeffrey Poulton	Chief Financial Officer
Ginger Gregory PhD	Chief Human Resources Officer
Bill Mordan	General Counsel and Corporate Secretary
Matthew Walker	Head, Technical Operations
Kim Stratton	Head of International Commercial

Investor relations

Sarah Elton-Farr
+44 1256 894157
seltonfarr@shire.com

Media relations

media@shire.com